Livzon Pharmaceutical Group Inc. (HKG: 1513)

Livzon Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021	Jan 1, 2020
Cash & Equivalents	10,733	11,326	10,411	9,146	9,954	8,855
Trading Asset Securities	76.47	81.79	108.09	182.77	25.98	17.19
Cash & Short-Term Investments	10,809	11,408	10,519	9,329	9,980	8,873
Cash Growth	3.64%	8.44%	12.76%	-6.52%	12.48%	3.12%
Accounts Receivable	3,421	3,575	4,039	3,294	2,892	2,425
Other Receivables	55.5	51.91	31.32	64.37	92.85	120.37
Receivables	3,476	3,627	4,071	3,358	2,985	2,546
Inventory	1,989	2,061	2,045	1,663	1,488	1,169
Other Current Assets	338.63	171.11	352	322.42	174.88	286
Total Current Assets	16,613	17,266	16,987	14,673	14,627	12,873
Property, Plant & Equipment	4,617	4,566	4,592	4,239	3,707	3,394
Long-Term Investments	1,661	1,670	1,738	1,695	988.09	651.24
Goodwill	124.91	124.91	103.04	103.04	103.04	103.04
Other Intangible Assets	410.43	426.28	557.44	260.28	236.43	229.56
Long-Term Deferred Tax Assets	328.05	301.92	283.89	252.69	238.23	182.66
Long-Term Deferred Charges	486.02	468.62	416.74	704.41	373.49	259.84
Other Long-Term Assets	668.5	221.17	189.66	444.62	317.09	283.33
Total Assets	24,909	25,045	24,868	22,372	20,591	17,976
Accounts Payable	1,717	1,658	1,862	1,817	1,625	1,270
Accrued Expenses	281.18	3,295	3,249	2,656	2,467	2,173
Short-Term Debt	2,050	1,860	1,622	2,043	1,551	1,361
Current Portion of Long-Term Debt	1,632	647.47	-	-	-	-
Current Portion of Leases	-	12.2	10.44	9.28	8.54	-
Current Income Taxes Payable	227.16	181.58	92.57	97.45	179.51	138.66
Current Unearned Revenue	79.01	138	226.19	167.8	104.45	151.77
Other Current Liabilities	3,027	294.49	334.42	134.34	147.17	199.46
Total Current Liabilities	9,013	8,087	7,397	6,925	6,083	5,294
Long-Term Debt	410.76	1,613	1,974	636.78	360.32	-
Long-Term Leases	8.44	9.03	11.61	5.27	10.1	-
Long-Term Unearned Revenue	244.19	269.37	273.21	258.88	276.14	246.68
Long-Term Deferred Tax Liabilities	206.87	209.81	191.96	156.89	143.28	90.88
Other Long-Term Liabilities	90	90	84	78	78	70
Total Liabilities	9,974	10,278	9,932	8,061	6,951	5,701
Common Stock	926.61	923.94	935.55	937.87	944.84	934.76
Additional Paid-In Capital	1,353	1,030	1,422	1,629	1,457	1,091
Retained Earnings	12,093	11,653	11,182	10,461	9,682	9,042
Treasury Stock	-321.17	-	-55.94	-71.21	-250.06	-
Comprehensive Income & Other	107.93	435.62	391.64	46.55	273.78	98.69
Total Common Equity	14,159	14,042	13,876	13,004	12,107	11,167
Minority Interest	777.19	724.21	1,060	1,307	1,533	1,108
Shareholders' Equity	14,936	14,767	14,936	14,311	13,640	12,275
Total Liabilities & Equity	24,909	25,045	24,868	22,372	20,591	17,976
Total Debt	4,101	4,141	3,619	2,694	1,930	1,361
Net Cash (Debt)	6,708	7,266	6,901	6,635	8,050	7,512
Net Cash Growth	4.52%	5.29%	4.01%	-17.58%	7.16%	5.76%
Net Cash Per Share	7.25	7.81	7.37	7.09	8.58	8.04
Filing Date Shares Outstanding	916.77	923.94	932.23	929.97	932.47	934.76
Total Common Shares Outstanding	916.77	923.94	932.23	929.97	944.84	934.76
Working Capital	7,600	9,179	9,591	7,748	8,544	7,580
Book Value Per Share	15.44	15.20	14.88	13.98	12.81	11.95
Tangible Book Value	13,623	13,491	13,216	12,640	11,768	10,834
Tangible Book Value Per Share	14.86	14.60	14.18	13.59	12.45	11.59
Buildings	-	-	-	3,123	2,970	2,864
Machinery	-	8,296	7,577	3,764	3,216	2,856
Construction In Progress	-	289.31	602.44	554.58	385.7	233.49

Source: S&P Capital IQ. Standard template. Financial Sources.